(Approval lapsed) ILEVRO (nepafenac ophthalmic suspension), 0.3%
Section 19A approved medicine
(Approval lapsed) ILEVRO (nepafenac ophthalmic suspension), 0.3%
Section 19A approval holder
Novartis Pharmaceuticals Australia Pty Ltd ABN 18 004 244 160
Phone
02 9805 3433
Approved until
Status
Expired
Medicines in short supply/unavailable
ILEVRO nepafenac 0.3% eye drops, suspension, bottle - ARTG 230200
Indication(s)
- Prevention and treatment of postoperative pain and inflammation associated with cataract surgery
- Reduction in risk of postoperative macular oedema associated with cataract surgery in patients with non-proliferative diabetic retinopathy